• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DHAI alert in real time by email

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors.

    Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financial Officer and Secretary of AIVITA Biomedical, Inc., an immuno-oncology company, Mr. Burell previously served as CFO of CombiMatrix Corporation through its successful acquisition by Invitae Corp. He has a proven track record in leading public and private debt and equity financing transactions, corporate reorganizations, and complex M&A activities. Mr. Burell also serves on the Board of Directors of Microbot Medical, Inc. (NASDAQ:MBOT), a medical device company specializing in micro-robotics technologies. He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University and is a certified public accountant.

    CEO, Jason Chen, stated: "We are pleased to welcome Scott Burell to our Board of Directors. Scott brings exceptional financial acumen and extensive experience in the life sciences sector, having successfully navigated complex transactions and capital market activities throughout his career. His deep understanding of medical technology companies and proven ability to drive value creation will strengthen our board as we continue executing our growth strategy."

    Mr. Burell commented on the appointment: "I am pleased to join DIH's Board of Directors and contribute to the company's mission of improving lives through advanced rehabilitation technologies. DIH's position in the growing rehabilitation robotics market presents significant opportunities, and I look forward to working with management and my fellow board members to support the company's continued success and value creation for shareholders."

    The Board of Directors now comprises six members, with four independent members, further strengthening the company's commitment to strong governance.

    About DIH Holding US, Inc.

    DIH stands for the vision to "Deliver Inspiration & Health" to improve the daily lives of millions of people with disabilities and functional impairments through providing devices and solutions enabling intensive rehabilitation. DIH is a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Built through the mergers of global-leading niche technology providers, DIH is a transformative rehabilitation solutions provider and consolidator of a largely fragmented and manual-labor-driven industry.

    Caution Regarding Forward-Looking Statements

    This press release contains certain statements which are not historical facts, which are forward-looking statements within the meaning of the federal securities laws, for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements include certain statements made with respect to the business combination, the services offered by DIH and the markets in which it operates, and DIH's projected future results. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions provided for illustrative purposes only, and projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These risks and uncertainties include, but are not limited to: general economic, political and business conditions; the ability of DIH to achieve its projected revenue, the failure of DIH realize the anticipated benefits of the recently-completed business combination and access to sources of additional debt or equity capital if needed. While DIH may elect to update these forward-looking statements at some point in the future, DIH specifically disclaims any obligation to do so.

    Investor Contact

    Louisa Smith

    Investor.relations@dih.com



    Primary Logo

    Get the next $DHAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHAI
    $MBOT

    CompanyDatePrice TargetRatingAnalyst
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    More analyst ratings

    $DHAI
    $MBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting

    HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year’s Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL. Last year’s meeting was the first time that endovascular robotics was featured at SRS, and with the Company’s FDA clearance less than a year ago and the growing adoption of the LIBERTY System at leading academic centers in the U.S. for a broad range of peripheral endovascular procedures, the Company believes the continued focus on this segment of the market underscores its increasing impo

    7/21/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026

    The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026. The performance ref

    7/7/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader

    HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. As momentum continues to rise in the U.S., reflected in increased accounts and usage across several states, and with the momentum building in the international markets as seen with the recent clearance in Israel and progress towards obtaining CE Mark as w

    6/30/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Madden Martin J.

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    4/3/26 4:30:41 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Stockburger Aileen Ptucha

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    4/3/26 4:30:43 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Wenderow Tal Baruch

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    4/3/26 4:30:40 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    SEC Filings

    View All

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    7/21/26 8:30:28 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    7/7/26 8:30:39 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    6/30/26 8:30:20 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Microbot Medical with a new price target

    Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50

    12/3/25 8:38:40 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DIH Holdings US Inc.

    SC 13G/A - DIH HOLDING US, INC. (0001883788) (Subject)

    11/14/24 6:07:49 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by DIH Holdings US Inc.

    SC 13G/A - DIH HOLDING US, INC. (0001883788) (Subject)

    11/14/24 12:46:18 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by DIH Holdings US Inc.

    SC 13D - DIH HOLDING US, INC. (0001883788) (Subject)

    2/20/24 5:18:47 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    $DHAI
    $MBOT
    Leadership Updates

    Live Leadership Updates

    View All

    Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations

    HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS). Lovell Government Services will become Company's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems. Lovel

    6/16/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

    Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City that attracts over 1,000 global experts across key target call points HINGHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, which is experiencing strong interest from physicians and hospital executives following the commencement of the Full Market Release of LIBERTY at the recent Soc

    5/5/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)

    Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S.  Strong physician interest at recent Society of Interventional Radiology conference and rising awareness across markets outside the U.S. supports commercial readiness throughout heavily populated regions HINGHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, is continuing to implement its growth strategy with the appointment of Alon Tamir as Vice President of Sales, Europe, the Middle East and Asia

    4/30/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DHAI
    $MBOT
    Financials

    Live finance-specific insights

    View All

    Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu

    Conference call and live webcast to be held Monday, May 18th at 3:00pm ET Wall Street firm publishes research report refuting claims made by recent unaffiliated third-party article; Research report also references Vascular Surgeon who categorically disputes many of the assertions that were attributed to him in same unaffiliated third-party article Company to review claims made in the unaffiliated third-party article, to correct certain misleading statements and misrepresentations to ensure the investing public is fully informed of the actual facts HINGHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® E

    5/15/26 9:56:07 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care